HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Yuji Takahashi Selected Research

fosphenytoin (Cerebyx)

5/2021Levetiracetam versus fosphenytoin as a second-line treatment after diazepam for status epilepticus: study protocol for a multicenter non-inferiority designed randomized control trial.
8/2020Phenytoin versus fosphenytoin for second-line treatment of status epilepticus: propensity score matching analysis using a nationwide inpatient database.
3/2020Changes in Real-world Practice Patterns of Antiepileptic Drugs for Status Epilepticus: A Nationwide Observational Study in Japan.
1/2020Levetiracetam vs. Fosphenytoin for Second-Line Treatment of Status Epilepticus: Propensity Score Matching Analysis Using a Nationwide Inpatient Database.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Yuji Takahashi Research Topics

Disease

20Neoplasms (Cancer)
04/2015 - 03/2002
12Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease)
03/2021 - 09/2010
11Coronary Artery Disease (Coronary Atherosclerosis)
08/2017 - 05/2008
10Parkinson Disease (Parkinson's Disease)
12/2020 - 07/2010
8Inflammation (Inflammations)
01/2021 - 11/2005
6Pancreatic Neoplasms (Pancreatic Cancer)
01/2008 - 08/2003
6Lung Neoplasms (Lung Cancer)
09/2006 - 03/2002
5Pain (Aches)
10/2022 - 04/2004
5Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker)
03/2022 - 07/2010
5Critical Illness (Critically Ill)
01/2022 - 10/2019
5Cardiovascular Diseases (Cardiovascular Disease)
01/2020 - 10/2009
5Hepatocellular Carcinoma (Hepatoma)
10/2016 - 11/2002
5Type 2 Diabetes Mellitus (MODY)
10/2016 - 06/2008
4Status Epilepticus (Complex Partial Status Epilepticus)
05/2021 - 01/2020
4Body Weight (Weight, Body)
01/2020 - 03/2004
4Liver Diseases (Liver Disease)
01/2018 - 09/2012
4Adenocarcinoma
07/2016 - 06/2002
4Atherosclerosis
10/2015 - 11/2014
4Carcinogenesis
09/2006 - 03/2002
3Muscular Diseases (Myopathy)
01/2022 - 10/2017
3Cognitive Dysfunction
07/2021 - 12/2020
3Infections
01/2021 - 01/2019
3Hypoxia (Hypoxemia)
01/2021 - 11/2002
3Fibrosis (Cirrhosis)
11/2020 - 11/2005
3Parkinsonian Disorders (Parkinsonism)
09/2018 - 07/2010
3Colonic Neoplasms (Colon Cancer)
01/2018 - 02/2012
3Dilated Cardiomyopathy (Cardiomyopathy, Congestive)
11/2011 - 09/2007
3Neoplasm Metastasis (Metastasis)
07/2011 - 03/2004
3Carcinoma (Carcinomatosis)
04/2004 - 06/2002
2Muscle Weakness
01/2022 - 05/2019
2Respiratory Insufficiency (Respiratory Failure)
06/2021 - 11/2017
2Wounds and Injuries (Trauma)
03/2021 - 04/2009
2Alzheimer Disease (Alzheimer's Disease)
03/2021 - 02/2008
2Interstitial Lung Diseases (Interstitial Lung Disease)
03/2021 - 03/2020
2Heart Failure
01/2020 - 06/2008
2Ketosis
01/2020 - 01/2002
2Dyskinesias (Dyskinesia)
01/2020 - 01/2020
2Spinocerebellar Ataxias (Spinocerebellar Ataxia)
12/2019 - 11/2009
2Disease Progression
08/2018 - 08/2017
2Epilepsy (Aura)
01/2018 - 02/2012
2Cerebellar Ataxia (Dysmetria)
02/2017 - 08/2013
2Dementia (Dementias)
02/2017 - 04/2015

Drug/Important Bio-Agent (IBA)

14Proteins (Proteins, Gene)FDA Link
01/2021 - 01/2002
11Biomarkers (Surrogate Marker)IBA
01/2022 - 07/2007
9Messenger RNA (mRNA)IBA
10/2016 - 06/2002
8Lipoproteins (Lipoprotein)IBA
06/2019 - 01/2002
6Indicators and Reagents (Reagents)IBA
01/2022 - 12/2003
6Pharmaceutical PreparationsIBA
03/2021 - 02/2008
6Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
07/2015 - 05/2009
5GemcitabineFDA Link
01/2008 - 01/2004
5ChromatesIBA
09/2006 - 03/2002
4LuciferasesIBA
05/2022 - 07/2006
4fosphenytoin (Cerebyx)FDA LinkGeneric
05/2021 - 01/2020
4NucleotidesIBA
09/2020 - 11/2002
4Levodopa (L Dopa)FDA LinkGeneric
01/2020 - 04/2019
4ProstaglandinsIBA
10/2019 - 08/2003
4MicroRNAs (MicroRNA)IBA
01/2016 - 07/2010
4Triglycerides (Triacylglycerol)IBA
10/2015 - 09/2012
4Toll-Like Receptor 4IBA
04/2015 - 08/2008
4Toll-Like Receptors (Toll-Like Receptor)IBA
04/2015 - 05/2008
4CytokinesIBA
02/2014 - 06/2008
4ChromiumIBA
09/2006 - 03/2002
3DystrophinIBA
03/2022 - 10/2020
3Glucose (Dextrose)FDA LinkGeneric
01/2022 - 03/2004
3Diazepam (Valium)FDA LinkGeneric
05/2021 - 01/2020
3RiluzoleFDA LinkGeneric
03/2021 - 03/2020
3LDL Lipoproteins (beta Lipoproteins)IBA
11/2020 - 09/2012
3PlasmalogensIBA
06/2019 - 05/2014
3Monoclonal AntibodiesIBA
09/2013 - 09/2012
3Histamine (Histamine Dihydrochloride)FDA Link
03/2010 - 04/2009
3LipopolysaccharidesIBA
10/2008 - 03/2004
3Streptozocin (Streptozotocin)FDA Link
10/2008 - 02/2003
3Fluorouracil (Carac)FDA LinkGeneric
01/2008 - 08/2006
2Analgesics (Analgesic Drugs)IBA
10/2022 - 01/2018
2THK5351IBA
01/2022 - 03/2021
2Levetiracetam (Keppra)FDA LinkGeneric
05/2021 - 01/2020
2ConnectinIBA
03/2021 - 01/2021
2Antisense OligonucleotidesIBA
01/2021 - 06/2006
2Blood Glucose (Blood Sugar)IBA
01/2021 - 06/2013
2Intravenous Immunoglobulins (IVIG)FDA Link
01/2021 - 01/2019
2AlbuminsIBA
12/2020 - 01/2020
2oxidized low density lipoproteinIBA
11/2020 - 09/2013
2Phenytoin (Dilantin)FDA LinkGeneric
08/2020 - 03/2020
2Anticonvulsants (Antiepileptic Drugs)IBA
08/2020 - 03/2020
2C-Reactive ProteinIBA
01/2020 - 10/2009
2CalciumIBA
01/2020 - 08/2017
2Carbidopa (Lodosyn)FDA LinkGeneric
01/2020 - 04/2019
2HDL CholesterolIBA
01/2019 - 11/2014
2Prion ProteinsIBA
02/2017 - 02/2016
2ColforsinIBA
10/2016 - 06/2013
2MucinsIBA
07/2016 - 01/2004
2Superoxide Dismutase-1IBA
10/2015 - 12/2013

Therapy/Procedure

12Therapeutics
03/2020 - 08/2006
5Critical Care (Surgical Intensive Care)
10/2022 - 01/2020
3Palliative Care (Palliative Therapy)
06/2021 - 09/2014
3Drug Therapy (Chemotherapy)
01/2020 - 03/2004
2Glycemic Control
01/2022 - 01/2021
2Length of Stay
03/2020 - 01/2020
2Gastrostomy
01/2020 - 04/2019
2Oral Administration
01/2020 - 08/2003